The United Laboratories International Holdings Limited (3933.HK)
- Previous Close
9.770 - Open
9.710 - Bid 9.480 x --
- Ask 9.550 x --
- Day's Range
9.430 - 9.720 - 52 Week Range
5.690 - 10.240 - Volume
6,034,388 - Avg. Volume
4,028,547 - Market Cap (intraday)
17.225B - Beta (5Y Monthly) 0.05
- PE Ratio (TTM)
5.89 - EPS (TTM)
1.610 - Earnings Date Mar 26, 2024
- Forward Dividend & Yield 0.43 (4.58%)
- Ex-Dividend Date Jun 17, 2024
- 1y Target Est
12.45
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin products, nervous system drugs, vitamins, veterinary drugs, and vacant gelatin capsules, as well as active pharmaceutical ingredients and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, rest of Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
www.tul.com.cn15,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 3933.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3933.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3933.HK
Valuation Measures
Market Cap
17.23B
Enterprise Value
14.24B
Trailing P/E
5.90
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.16
Price/Book (mrq)
1.25
Enterprise Value/Revenue
1.04
Enterprise Value/EBITDA
4.18
Financial Highlights
Profitability and Income Statement
Profit Margin
19.66%
Return on Assets (ttm)
9.92%
Return on Equity (ttm)
23.13%
Revenue (ttm)
13.74B
Net Income Avi to Common (ttm)
2.7B
Diluted EPS (ttm)
1.610
Balance Sheet and Cash Flow
Total Cash (mrq)
4.26B
Total Debt/Equity (mrq)
11.80%
Levered Free Cash Flow (ttm)
--
Research Analysis: 3933.HK
Company Insights: 3933.HK
3933.HK does not have Company Insights